First Time Loading...

Bicycle Therapeutics PLC
NASDAQ:BCYC

Watchlist Manager
Bicycle Therapeutics PLC Logo
Bicycle Therapeutics PLC
NASDAQ:BCYC
Watchlist
Price: 22.67 USD -0.04% Market Closed
Updated: Apr 25, 2024

Intrinsic Value

BCYC's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserv... [ Read More ]

The intrinsic value of one BCYC stock under the Base Case scenario is 11.23 USD. Compared to the current market price of 22.67 USD, Bicycle Therapeutics PLC is Overvalued by 50%.

Key Points:
BCYC Intrinsic Value
Base Case
11.23 USD
Overvaluation 50%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Bicycle Therapeutics PLC

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling BCYC stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Bicycle Therapeutics PLC

Provide an overview of the primary business activities
of Bicycle Therapeutics PLC.

What unique competitive advantages
does Bicycle Therapeutics PLC hold over its rivals?

What risks and challenges
does Bicycle Therapeutics PLC face in the near future?

Has there been any significant insider trading activity
in Bicycle Therapeutics PLC recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Bicycle Therapeutics PLC.

Provide P/S
for Bicycle Therapeutics PLC.

Provide P/E
for Bicycle Therapeutics PLC.

Provide P/OCF
for Bicycle Therapeutics PLC.

Provide P/FCFE
for Bicycle Therapeutics PLC.

Provide P/B
for Bicycle Therapeutics PLC.

Provide EV/S
for Bicycle Therapeutics PLC.

Provide EV/GP
for Bicycle Therapeutics PLC.

Provide EV/EBITDA
for Bicycle Therapeutics PLC.

Provide EV/EBIT
for Bicycle Therapeutics PLC.

Provide EV/OCF
for Bicycle Therapeutics PLC.

Provide EV/FCFF
for Bicycle Therapeutics PLC.

Provide EV/IC
for Bicycle Therapeutics PLC.

Show me price targets
for Bicycle Therapeutics PLC made by professional analysts.

What are the Revenue projections
for Bicycle Therapeutics PLC?

How accurate were the past Revenue estimates
for Bicycle Therapeutics PLC?

What are the Net Income projections
for Bicycle Therapeutics PLC?

How accurate were the past Net Income estimates
for Bicycle Therapeutics PLC?

What are the EPS projections
for Bicycle Therapeutics PLC?

How accurate were the past EPS estimates
for Bicycle Therapeutics PLC?

What are the EBIT projections
for Bicycle Therapeutics PLC?

How accurate were the past EBIT estimates
for Bicycle Therapeutics PLC?

Compare the revenue forecasts
for Bicycle Therapeutics PLC with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Bicycle Therapeutics PLC and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Bicycle Therapeutics PLC against its competitors.

Analyze the profit margins
(gross, operating, and net) of Bicycle Therapeutics PLC compared to its peers.

Compare the P/E ratios
of Bicycle Therapeutics PLC against its peers.

Discuss the investment returns and shareholder value creation
comparing Bicycle Therapeutics PLC with its peers.

Analyze the financial leverage
of Bicycle Therapeutics PLC compared to its main competitors.

Show all profitability ratios
for Bicycle Therapeutics PLC.

Provide ROE
for Bicycle Therapeutics PLC.

Provide ROA
for Bicycle Therapeutics PLC.

Provide ROIC
for Bicycle Therapeutics PLC.

Provide ROCE
for Bicycle Therapeutics PLC.

Provide Gross Margin
for Bicycle Therapeutics PLC.

Provide Operating Margin
for Bicycle Therapeutics PLC.

Provide Net Margin
for Bicycle Therapeutics PLC.

Provide FCF Margin
for Bicycle Therapeutics PLC.

Show all solvency ratios
for Bicycle Therapeutics PLC.

Provide D/E Ratio
for Bicycle Therapeutics PLC.

Provide D/A Ratio
for Bicycle Therapeutics PLC.

Provide Interest Coverage Ratio
for Bicycle Therapeutics PLC.

Provide Altman Z-Score Ratio
for Bicycle Therapeutics PLC.

Provide Quick Ratio
for Bicycle Therapeutics PLC.

Provide Current Ratio
for Bicycle Therapeutics PLC.

Provide Cash Ratio
for Bicycle Therapeutics PLC.

What is the historical Revenue growth
over the last 5 years for Bicycle Therapeutics PLC?

What is the historical Net Income growth
over the last 5 years for Bicycle Therapeutics PLC?

What is the current Free Cash Flow
of Bicycle Therapeutics PLC?

Discuss the annual earnings per share (EPS)
trend over the past five years for Bicycle Therapeutics PLC.

Financials

Balance Sheet Decomposition
Bicycle Therapeutics PLC

Current Assets 561.9m
Cash & Short-Term Investments 526.4m
Receivables 24m
Other Current Assets 11.4m
Non-Current Assets 33.5m
PP&E 27.7m
Other Non-Current Assets 5.8m
Current Liabilities 69.5m
Accounts Payable 13.1m
Accrued Liabilities 31.3m
Other Current Liabilities 25.2m
Non-Current Liabilities 154.9m
Long-Term Debt 30.7m
Other Non-Current Liabilities 124.2m
Efficiency

Earnings Waterfall
Bicycle Therapeutics PLC

Revenue
27m USD
Operating Expenses
-216.3m USD
Operating Income
-189.4m USD
Other Expenses
8.7m USD
Net Income
-180.7m USD

Free Cash Flow Analysis
Bicycle Therapeutics PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

BCYC Profitability Score
Profitability Due Diligence

Bicycle Therapeutics PLC's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Exceptional 1-Year Revenue Growth
Positive Revenue Growth Forecast
Declining ROE
23/100
Profitability
Score

Bicycle Therapeutics PLC's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

BCYC Solvency Score
Solvency Due Diligence

Bicycle Therapeutics PLC's solvency score is 52/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
52/100
Solvency
Score

Bicycle Therapeutics PLC's solvency score is 52/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BCYC Price Targets Summary
Bicycle Therapeutics PLC

Wall Street analysts forecast BCYC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BCYC is 44.06 USD with a low forecast of 30.3 USD and a high forecast of 63 USD.

Lowest
Price Target
30.3 USD
34% Upside
Average
Price Target
44.06 USD
94% Upside
Highest
Price Target
63 USD
178% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

BCYC Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

BCYC Price
Bicycle Therapeutics PLC

1M 1M
-11%
6M 6M
+50%
1Y 1Y
+14%
3Y 3Y
-28%
5Y 5Y
+89%
10Y 10Y
+89%
Annual Price Range
22.67
52w Low
13.29
52w High
28.67
Price Metrics
Average Annual Return 59.42%
Standard Deviation of Annual Returns 118.11%
Max Drawdown -79%
Shares Statistics
Market Capitalization 858.7m USD
Shares Outstanding 37 880 300
Percentage of Shares Shorted 6.79%

BCYC Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Bicycle Therapeutics PLC Logo
Bicycle Therapeutics PLC

Country

United Kingdom

Industry

Biotechnology

Market Cap

858.7m USD

Dividend Yield

0%

Description

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The company is headquartered in Cambridge, Cambridgeshire and currently employs 119 full-time employees. The company went IPO on 2019-05-23. The firm is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC) targeting EphA2, and BT8009, a second-generation BTC targeting Nectin-4, a tumor antigen in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets membrane type 1 matrix metalloproteinase (MT1-MMP) is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the center for drug development of cancer research United Kingdom. The Company’s immune-oncology products include BT7480, BT7455 and BT7401. BT7480 is a TICA that targets CD137 and Nectin-4. BT7455 is a TICA targeting EphA2 and CD137. BT7401 is an agonistic Bicycle built from multiple CD137 monomeric Bicycles.

Contact

CAMBRIDGESHIRE
Cambridge
Babraham Hall
+11441223261503.0
https://www.bicycletherapeutics.com/

IPO

2019-05-23

Employees

119

Officers

CEO & Executive Director
Dr. Kevin Lee M.B.A., Ph.D.
Co-Founder & Non-Executive Director
Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE
Chief Operating Officer
Mr. Alistair Milnes
Chief Technology Officer
Dr. Michael Skynner B.sc. Ph.d., Ph.D.
Scientific Founder
Dr. Christian Heinis
Chief Financial Officer
Ms. Alethia Rene Young
Show More
Senior VP, Chief Accounting Officer & Principal Accounting Officer
Mr. Travis Thompson
Chief Scientific Officer
Dr. Nicholas Keen Ph.D.
General Counsel
Mr. Zafar Qadir
Senior Vice President of Capital Markets & Corporate Communications
Mr. David E. Borah CFA
Show Less

See Also

Discover More
What is the Intrinsic Value of one BCYC stock?

The intrinsic value of one BCYC stock under the Base Case scenario is 11.23 USD.

Is BCYC stock undervalued or overvalued?

Compared to the current market price of 22.67 USD, Bicycle Therapeutics PLC is Overvalued by 50%.